Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia Cells
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retinoids, which are derivatives of vitamin A, induce differentiation of acute promyelocytic leukemia (APL) cells in vitro and in patients. However, APL cells develop resistance to retinoic acid treatment. Arsenic trioxide (As2O3) can induce clinical remission in patients with APL, including those who have relapsed after retinoic acid treatment, by inducing apoptosis (programmed cell death) of the leukemia cells. In this study, we investigated the molecular mechanisms by which As2O3 induces apoptosis in retinoic acid-sensitive NB4 APL cells, in retinoic acid-resistant derivatives of these cells, and in fresh leukemia cells from patients. METHODS: Apoptosis was assessed by means of DNA fragmentation analyses, TUNEL assays (i.e., deoxyuridine triphosphate labeling of DNA nicks with terminal deoxynucleotidyl transferase), and flow cytometry. Expression of the PML/RAR alpha fusion protein in leukemia cells was assessed by means of western blotting, ligand binding, and immunohistochemistry. Northern blotting and ribonuclease protection assays were used to evaluate changes in gene expression in response to retinoic acid and As2O3 treatment. RESULTS AND CONCLUSIONS: As2O3 induces apoptosis without differentiation in retinoic acid-sensitive and retinoic acid-resistant APL cells at concentrations that are achievable in patients. As2O3 induces loss of the PML/RAR alpha fusion protein in NB4 cells, in retinoic-acid resistant cells derived from them, in fresh APL cells from patients, and in non-APL cells transfected to express this protein. As2O3 and retinoic acid induce different patterns of gene regulation, and they inhibit the phenotypes induced by each other. Understanding the molecular basis of these differences in the effects of As2O3 and retinoic acid may guide the clinical use of arsenic compounds and provide insights into the management of leukemias that do not respond to retinoic acid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., & Rutter, W. J. (1979) · Biochemistry · doi:10.1021/bi00591a005 · Cited by 21,725
Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., & Green, M. R. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.18.7035 · Cited by 6,324
Shen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Kakizuka, A., Miller, W. H., Umesono, K., Warrell, R. P., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., & Evans, R. M. (1991) · Cell · doi:10.1016/0092-8674(91)90112-c · Cited by 1,427
Self-citationde Thé, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., & Dejean, A. (1991) · Cell · doi:10.1016/0092-8674(91)90113-d · Cited by 1,343
Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)
Warrell, R. P., Frankel, S. R., Miller, W. H., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Andreeff, M., Tafuri, A., Jakubowski, A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105163242002 · Cited by 1,251
Self-citationCastaigne, S., Chomienne, C., Daniel, M., Ballerini, P., Berger, R., Fenaux, P., & Degos, L. (1990) · Blood · doi:10.1182/blood.v76.9.1704.1704 · Cited by 1,184
Identification of two distinct regulatory regions adjacent to the human β-interferon gene
Zinn, K., Dimaio, D., & Maniatis, T. (1983) · Cell · doi:10.1016/0092-8674(83)90544-5 · Cited by 1,038
Lanotte, M., Martin-Thouvenin, V, Najman, S., Balerini, P., Valensi, F., & Berger, R. (1991) · Blood · doi:10.1182/blood.v77.5.1080.1080 · Cited by 883
Chen, G., Zhu, J., Shi, X., Ni, J., Zhong, H., Si, G., Jin, X., Tang, W., Li, X., Xong, S., et al. (1996) · Blood · doi:10.1182/blood.v88.3.1052.1052 · Cited by 864
Cited by
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Self-citationComplete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
Melnick, A., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,028
RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation
Tatham, M. H., Geoffroy, M.-C., Shen, L., Plechanovova, A., Hattersley, N., Jaffray, E. G., Palvimo, J. J., & Hay, R. T. (2008) · Nature Cell Biology · doi:10.1038/ncb1716 · Cited by 847
Arsenic degrades PML or PML–RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway
Lallemand-Breitenbach, V., Jeanne, M., Benhenda, S., Nasr, R., Lei, M., Peres, L., Zhou, J., Zhu, J., Raught, B., & de Thé, H. (2008) · Nature Cell Biology · doi:10.1038/ncb1717 · Cited by 734
Niu, C., Yan, H., Yu, T., Sun, H.-P., Liu, J.-X., Li, X.-S., Wu, W., Zhang, F.-Q., Chen, Y., Zhou, L., et al. (1999) · Blood · doi:10.1182/blood.v94.10.3315.422k16_3315_3324 · Cited by 625
Self-citationShen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400053101 · Cited by 583
Self-citationLallemand-Breitenbach, V., & de The, H. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000661 · Cited by 563
Jing, Y., Dai, J., Chalmers-Redman, R. M. E., Tatton, W. G., & Waxman, S. (1999) · Blood · doi:10.1182/blood.v94.6.2102 · Cited by 543
Self-citationInhibition of Mitochondrial Respiration
Pelicano, H., Feng, L., Zhou, Y., Carew, J. S., Hileman, E. O., Plunkett, W., Keating, M. J., & Huang, P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301546200 · Cited by 495
Lallemand-Breitenbach, V., Zhu, J., Puvion, F., Koken, M., Honoré, N., Doubeikovsky, A., Duprez, E., Pandolfi, P. P., Puvion, E., Freemont, P., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.12.1361 · Cited by 488
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Self-citationAcute promyelocytic leukemia: evolving therapeutic strategies
Tallman, M. S., Nabhan, C., Feusner, J. H., & Rowe, J. M. (2002) · Blood · doi:10.1182/blood.v99.3.759 · Cited by 398
Platzbecker, U., Avvisati, G., Cicconi, L., Thiede, C., Paoloni, F., Vignetti, M., Ferrara, F., Divona, M., Albano, F., Efficace, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1982 · Cited by 389
Self-citationDilda, P. J., & Hogg, P. J. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.05.001 · Cited by 389
An Emerging Role for Epigenetic Dysregulation in Arsenic Toxicity and Carcinogenesis
Ren, X., McHale, C. M., Skibola, C. F., Smith, A. H., Smith, M. T., & Zhang, L. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1002114 · Cited by 358
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Peres, L., Berthier, C., Rousselot, P., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354
What has traditional Chinese medicine delivered for modern medicine?
Wang, J., Wong, Y.-K., & Liao, F. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.3 · Cited by 328
Zhou, Y., Hileman, E. O., Plunkett, W., Keating, M. J., & Huang, P. (2003) · Blood · doi:10.1182/blood-2002-08-2512 · Cited by 327
How acute promyelocytic leukaemia revived arsenic
Zhu, J., Chen, Z., Lallemand-Breitenbach, V., & de Thé, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc887 · Cited by 321
Lallemand-Breitenbach, V., Guillemin, M.-C., Janin, A., Daniel, M.-T., Degos, L., Kogan, S. C., Michael Bishop, J., & de Thé, H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1043 · Cited by 305
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
de Thé, H., Pandolfi, P. P., & Chen, Z. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.002 · Cited by 297
Differentiation therapy of human cancer: basic science and clinical applications
Leszczyniecka, M., Roberts, T., Dent, P., Grant, S., & Fisher, P. B. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00132-2 · Cited by 292
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Malaney, P., Nicosia, S. V., & Davé, V. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.010 · Cited by 289
Roboz, G. J., Dias, S., Lam, G., Lane, W. J., Soignet, S. L., Warrell, R. P., & Rafii, S. (2000) · Blood · doi:10.1182/blood.v96.4.1525 · Cited by 275
Zhu, X.-H., Shen, Y.-L., Jing, Y.-K., Cai, X., Jia, P.-M., Huang, Y., Tang, W., Shi, G.-Y., Sun, Y.-P., Dai, J., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.9.772 · Cited by 272
Self-citationRetinoids in chemoprevention and differentiation therapy
Hansen, L. A., Sigman, C. C., Andreola, F., Ross, S. A., Kelloff, G. J., & Luca, L. M. D. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.271 · Cited by 270
Cai, X., Shen, Y.-L., Zhu, Q., Jia, P.-M., Yu, Y., Zhou, L., Huang, Y., Zhang, J.-W., Xiong, S.-M., Chen, S.-J., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401650 · Cited by 260
Jing, Y., Wang, L., Xia, L., Chen, G.-Q., Chen, Z., Miller, W. H., & Waxman, S. (2001) · Blood · doi:10.1182/blood.v97.1.264 · Cited by 204
Self-citationWang, R., Xia, L., Gabrilove, J., Waxman, S., & Jing, Y. (2013) · Leukemia · doi:10.1038/leu.2012.180 · Cited by 85
Self-citationThe Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?
Ablain, J., Nasr, R., Bazarbachi, A., & de Thé, H. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0087 · Cited by 44
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia
Matsui, W., Douglas Smith, B., Vala, M., Beal, N., Huff, C. A., Diehl, L. F., & Jones, R. J. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05395.x · Cited by 23
“ATO is clinically effective in the treatment of APL relapsing after therapy with ATRA and has multiple effects on APL cells including inhibiting cellular growth, inducing apoptosis, and promoting differentiation (Shao et al, 1998; Soignet et al, 1998; Cai et al, 2000; Miller et al, 2002).”
BackgroundResult
Metadata
- Authors
- Shao, W., Fanelli, M., Ferrara, F. F., Riccioni, R., Rosenauer, A., Davison, K., Lamph, W. W., Waxman, S., Pelicci, P. G., Lo Coco, F., Avvisati, G., Testy, U., Peschle, C., Gambacorti-Passerini, C., Nervi, C., & Miller, W. H.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01-21
- Volume
- 90
- Issue
- 2
- Pages
- 124-133
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2133935930
- Cited by
- 344
- References
- 47
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.